Intravitreal Adalimumab

PreclinicalMonoclonal antibody

Intravitreal Adalimumab is one of 3 small molecule programs targeting Retinitis Pigmentosa (RP). It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Retinitis Pigmentosa (RP)Active, not recruiting

Retinitis Pigmentosa (RP)Preclinical

Active, not recruiting

Competition

Competitive Landscape

2 competitors in Retinitis Pigmentosa (RP)

#DrugCompanyPhaseTrials

N-Acetylcysteine Amide

NNacuity Pharmaceuticals, Inc.

Phase 3

1 2

Intravitreal Injection of Ultevursen

LLaboratoires Thea

Phase 2

1 3

Intravitreal Adalimumab

CCentro de Pesquisa Rubens Siqueira

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

PreclinicalActive, not recruiting

Retinitis Pigmentosa (RP)

NCT07348588

Clinical

Trials by Indication[1]

Retinitis Pigmentosa (RP)1 trial

Intravitreal Adalimumab in Inherited and Degenerative Retinal Diseases: A Prospective Comparative Pilot Study

Active, not recruiting·CCentro de Pesquisa Rubens Siqueira·Preclinical·NCT07348588·30 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Intravitreal Adalimumab. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Intravitreal Adalimumab compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Intravitreal Adalimumab. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Centro de Pesquisa Rubens Siqueira company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Monoclonal antibody[2]
Highest Phase: Preclinical[1]
Company: CCentro de Pesquisa Rubens Siqueira

Intravitreal Adalimumab

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2026

Trials by Indication[1]

Retinitis Pigmentosa (RP)1 trial

References

Drug Info

Quick Facts

Related News